Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

HCA Healthcare’s April 2024 Update: Share Sale, Patient‑Care Push, & Shareholder Value Strategy

HCA Healthcare’s April 2024 update shows steady share movements, new patient‑centered NICU programs, and a robust shareholder return strategy that boosts value while strengthening quality care.

Dr. Sarah Winters

07/04/2026, 18:15

2 minutes to read

UHS Q1 2026 Earnings: Release, Call, & Key Financial Insights

UHS’s Q1‑2026 earnings release on April 27 and a follow‑up investor call will reveal revenue trends, capital spend, and early mental‑health integration gains—insightful data for investors, hospitals, and patients alike.

Dr. Sarah Winters

07/04/2026, 15:27

4 minutes to read

CVS Health’s Eye‑Drop Recall: Share Price Dip, Strengthening Safety Protocols, and Growth Outlook

CVS Health’s recent eye‑drop recall spurred a brief share price dip, yet robust earnings, specialty pharmacy growth, and digital health plans keep the company poised for long‑term resilience and regulatory‑compliant growth.

Dr. Sarah Winters

06/04/2026, 22:15

4 minutes to read

Valneva Keeps TBE Vaccine Demand Strong Amid Global Vaccine Market Decline

Valneva’s TBE vaccine stays in demand despite a shrinking global market thanks to 92.3% efficacy, a low adverse‑event profile, and fast regulatory approval in Europe and the U.S.

Dr. Sarah Winters

06/04/2026, 08:03

3 minutes to read

Abbott Laboratories: Institutional Moves & New Product Pipeline in 2026

Abbott Laboratories sees modest institutional buying in April 2026, amid a promising pipeline of CardioGuard, NeuroProtect, and InfiniScan—new therapies poised for FDA approval and market impact.

Dr. Sarah Winters

06/04/2026, 05:25

3 minutes to read

Elevance Health Shares Rise: Institutional Buyers Boost ELV Amid Insurance Market Trends

Institutional investors buy more Elevance Health shares amid rising health‑insurance premiums. Discover why ELV’s quiet activity matters for investors, hospitals, and policy makers.

Dr. Sarah Winters

06/04/2026, 05:15

2 minutes to read

Veeva Systems’ Executives Update Holdings via Zero‑Cost Internal Transfers, No Market Impact

Veeva Systems’ recent Form 4 filings show senior officers transferring internal equity awards at zero market value—routine adjustments that keep shareholder trust intact.

Dr. Sarah Winters

05/04/2026, 16:12

2 minutes to read

Institutional Inflows & Insider Moves Boost Bristol‑Myers Squibb’s Stock Confidence Amid Revenue Growth

Corporate‑Market Update: Bristol‑Myers Squibb (BMY) shows steady institutional inflows, routine insider transactions, bullish call‑option volume, and solid revenue growth despite a modest EPS miss, underscoring continued confidence in BMY’s pipeline…

Dr. Sarah Winters

05/04/2026, 00:21

3 minutes to read

WuXi AppTec Gains Momentum: Institutional Buy, Conference Award & Market Upswing

WuXi AppTec’s “Buy” rating and award‑winning role boost confidence for investors while short‑selling warns of China’s regulatory risk—see how the biopharma leader shapes future growth.

Dr. Sarah Winters

03/04/2026, 08:53

3 minutes to read

How Bayer’s Voting‑Rights Disclosure, EU Regulation Push, and Gene‑Therapy Breakthrough Shape Pharma Innovation

Explore Bayer’s latest voting‑rights disclosure, push for streamlined EU regulation and its breakthrough gene‑therapy for heart failure—why these moves matter for investors and patients alike.

Dr. Sarah Winters

03/04/2026, 01:18

4 minutes to read

Older articles